Table III.

Hematological and non-hematological toxicity in patients treated with gemcitabine/docetaxel or pemetrexed/cisplatin.

	Gemcitabine/docetaxel group (56 courses), n (%)			Pemetrexed/cisplatin group (48 courses), n (%)
Toxic event	Grade 1/2	Grade 3	Grade 4	Grade 1/2	Grade 3	Grade 4
Anemia	32 (57.1)	3 (5.3)	1 (1.8)	21 (43.7)	1 (2.0)	0 (0.0)
Leucopenia	30 (53.5)	12 (21.4)	5 (8.9)	11 (22.9)	2 (4.1)	0 (0.0)
Thrombocytopenia	26 (46.4)	7 (12.5)	2 (3.6)	8 (16.7)	0 (0.0)	0 (0.0)
Nausea and vomiting	18 (32.1)	3 (5.3)	0 (0.0)	20 (41.7)	2 (4.1)	0 (0.0)
Fatigue	22 (39.2)	6 (10.7)	2 (3.6)	21 (43.7)	3 (6.3)	0 (0.0)
Impaired liver function	5 (8.9)	0 (0.0)	0 (0.0)	12 (25.0)	0 (0.0)	0 (0.0)
Impaired kidney function	2 (3.5)	0 (0.0)	0 (0.0)	1 (2.0)	0 (0.0)	0 (0.0)
Alopecia	12 (21.4)	0 (0.0)	0 (0.0)	13 (27)	0 (0.0)	0 (0.0)

Toxicity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0) (37).